Fulgent Genetics Inc Stock News

Fulgent's core genetic testing business is recovering and should improve even further due to synergies with the COVID-19 business. Many people thought COVID-19 would dissipate in 2021 as the vaccine i

Both of these stocks are up more than 300% in 2020 and have room to run.

Helping the world cope with a pandemic increased sales by several multiples for these companies.

Investors in fast-moving biotechs made out like bandits.

Following a competitive process, Fulgent was selected to extend its support of the NYC DOE public school testing managed by the NYC Test and Trace Corps with on-site staffing and RT-PCR tests through

Could this genetic testing provider turn its coronavirus bump into long-term share price growth?

We discuss four MedTech stocks, CDNA, FLGT, OMI and QDEL that more than doubled in 2020, and are poised to maintain market beating momentum in 2021 on strong fundamentals.

Companies with fast growth and predictable trends are better bets in a frothy market.

Should you invest in shares of this high-flying coronavirus stock before it's too late?

The encore to a great 2019: Even more gains this year.

Although vaccine makers are dominating headlines, these diagnostic companies will remain relevant in the fight against COVID-19.

The COVID-19 pandemic continues to provide a tailwind for the genetic testing specialist.

There are plenty of healthcare stocks that have seen share growth this year. Here are three lesser-known stocks that have the potential to continue that growth this month and beyond.

Investors have been selling these stocks, but patient investors should take advantage of the opportunity.

Wall Street seems worried that the arrival of coronavirus vaccines will take the wind out of the sails of this genetic and medical testing company. That view misses the big picture.